Articles tagged "Antibodies"

2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
S. C. Jordan¹, R. Vescio², M. Toyoda³, N. Ammerman¹, E. Huang¹, A. Peng¹, S. Sethi¹, R. Najjar¹, K. Lim¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…
2019 American Transplant Congress
Solving Target Recognition and Activation Mediated by Non-HLA Agonistic Antibodies Targeting ETAR
A. Philippe¹, R. Catar¹, P. Scheerer², M. Szczepek², D. Dragun¹
¹Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany, ²Institute of Medical Physics and Biophysics, Charité Universitätsmedizin Berlin, Berlin, Germany
*Purpose: Endothelin-1 type A receptor (ETAR) exhibits multiligand binding abilities and may signal upon natural ligand Endothelin-1 (ET-1) and non-HLA ETAR-agonistic IgG (ETAR-IgG)-mediated stimulation similar…
2019 American Transplant Congress
Development of Non-Human Leukocyte Antigen Antibodies in Cardiac Antibody-Mediated Rejection
S. B. See¹, B. S. Mantell², K. J. Clerkin³, B. Ray⁴, E. R. Vasilescu⁵, C. Marboe⁵, Y. Naka⁶, S. Restaino¹, P. C. Colombo³, L. J. Addonizio², M. A. Farr³, E. Zorn¹
¹Columbia Center for Translational Immunology, Columbia University, New York, NY, ²Department of Pediatrics, Columbia University, New York, NY, ³Division of Cardiology, Columbia University, New York, NY, ⁴Immucor, Georgia, GA, ⁵Department of Pathology and Cell Biology, Columbia University, New York, NY, ⁶Department of Surgery, Columbia University, New York, NY
*Purpose: Antibody-mediated rejection (AMR), mainly driven by the development of donor-specific antibodies (DSA) directed against mismatched donor class I and class II HLA, is a…
2019 American Transplant Congress
Desensitization Using Only Polyvalent Immunoglobulins (IVIG) for Kidney Transplantation with Living Donors (LD)
L. R. Ulisses, J. O. Paixão, P. S. Souza, G. Bezerra, H. Rodrigues, N. Panajatopoulos, F. J. De Paula, E. David-Neto, M. C. R Castro
Renal Transplant Service, Renal Transplant Service, Hospital das Clinicas and Laboratory of Immunology-LIM-19, Medical School of te University of São Paulo, São Paulo, Brazil, São Paulo, Brazil
*Purpose: HLA sensitization is a barrier for kidney transplantation. Sensitized patients stay longer on the waiting list and have higher mortality rate and complications while…
2019 American Transplant Congress
Effect of Race and Antibody-Mediated Injury on Outcomes after Early Subclinical Inflammation
E. P. Kasik, M. E. Seifert, M. Bernard, G. Agarwal, H. Fatima, R. Gaston, B. Julian, C. Kew, V. Kumar, S. Mehta, S. Ong, F. Rosenblum, G. Towns, R. B. Mannon
University of Alabama, Birmingham, AL
*Purpose: The impact of subclinical inflammation (SCI) on transplant outcomes has been variable, based on previous studies in homogeneous cohorts with relatively low immunologic risk.…
2019 American Transplant Congress
Evaluation of Influenza Virus Antibody Response in Naturally Infected and Vaccinated Transplant Recipients by Protein Microarray
C. Hirzel, A. Chruscinski, V. H. Ferreira, A. G. L'Huillier, A. Humar, D. Kumar
University Health Network, Toronto, ON, Canada
*Purpose: Influenza A virus (IAV) infection is known to be an important cause of morbidity in solid organ transplant (SOT) recipients. The objective of our…
2019 American Transplant Congress
Kidney Allograft Recipient Absence of Myeloperoxidase Decreases Donor-Specific Antibody Titers and Attenuates Antibody-Mediated Allograft Rejection
S. Miyairi, N. Dvorina, A. Valujuskikh, W. M. Baldwin 3rd, R. L. Fairchild
Immunology, Cleveland Clinic Lerner Institute, Cleveland, OH
*Purpose: The incidence of antibody-mediated kidney graft rejection continues to increase. We previously reported that dysregulated donor-specific antibody (DSA) responses were induced in B6.CCR5-/- mice…
2019 American Transplant Congress
Desensitization Using Only IVIG: Is That an Option for Highly-Sensitized Patients Waiting for Kidneys from Cadaveric Donors?
J. O. Paixão, L. R. Ulisses, P. S. Souza, G. Bezerra, F. Agena, H. P. Rodrgues, N. Panajotopoulos, F. J. Paula, E. David-Neto, M. R. Castro
Nefrologia, Hospital das Clínicas da Universidade de São Paulo, São Paulo, Brazil
*Purpose: The reduction of anti-HLA has been proven to be efficient and safe in transplants of highly-sensitized with living donors (LD). The results of adopting…
2019 American Transplant Congress
Pre-emptive Ivig For Dsa Positive Living Donor Kidney Transplant Recipients
B. Abdalla¹, D. Kellner², A. Diaz², Y. Zheng³, E. Reed⁴, Q. J. Zhang⁴
¹Medicine, Division of Nephrology, David Geffen School of Medicine at UCLA, Los Angeles, CA, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³UCLA Immunogenetics Center, Los Angeles, CA, ⁴Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA
*Purpose: Intravenous immunoglobulin (IVIG) is used in desensitization regimens to modulate anti-human leukocyte antigen (HLA) donor-specific antibody (DSA) to facilitate transplantation of sensitized patients, however,…
2019 American Transplant Congress
Donor Derived Cell Free DNA Initiates De-Novo Donor Specific Antibody (DSA) Responses
S. Jordan¹, D. Sawinski², S. Dholakia³
¹Cedars-Sinai, Los Angeles, CA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³CareDx, Brisbane, CA
*Purpose: We hypothesize that subclinical inflammation, resulting in molecular injury, may contribute to sensitization of the recipients’ immune system. Antigenic presentation of donor-derived nucleic acids,…